keyword
https://read.qxmd.com/read/38351647/secondary-bladder-and-colorectal-cancer-after-treatments-for-prostate-cancer-a-population-based-study
#21
JOURNAL ARTICLE
Patricia Grisel Quintana Bárcena, Armen Garo Aprikian, Alice Dragomir
BACKGROUND: Prostate cancer (PCa) patients receiving radiotherapy may be predisposed to secondary malignancies. This study aimed to determine the association between PCa treatments, including radical prostatectomy (RP), external beam radiation therapy (EBRT), brachytherapy (BT) and androgen deprivation therapy (ADT); and secondary bladder and colorectal cancer. METHODS: A cohort study was constructed using Quebec administrative databases (Med-Echo and RAMQ). Included men were diagnosed and treated for PCa between 2000 and 2016...
February 13, 2024: Cancer Medicine
https://read.qxmd.com/read/38351013/review-of-brachytherapy-clinical-trials-a-cross-sectional-analysis-of-clinicaltrials-gov
#22
REVIEW
David Chen, Rod Parsa, Kabir Chauhan, Jelena Lukovic, Kathy Han, Amandeep Taggar, Srinivas Raman
INTRODUCTION: Characterizing the landscape of clinical trials including brachytherapy can provide an overview of the current status and research trends which may guide further areas of investigation. METHOD: We queried 449,849 clinical trials from the ClinicalTrials.gov registry using brachytherapy-related keywords from 1980 to 2023, yielding 245 multi-arm and 201 single-arm, brachytherapy trials. Multi-arm and single-arm brachytherapy trials were compared using 12 trial protocol elements...
February 13, 2024: Radiation Oncology
https://read.qxmd.com/read/38348896/nonsurgical-salvage-options-for-locally-recurrent-prostate-cancer-after-primary-definitive-radiotherapy-a-systematic-review-and-meta-analysis
#23
JOURNAL ARTICLE
Jie Yang, Xingyu Xiong, Xinyang Liao, Weitao Zheng, Hang Xu, Lu Yang, Qiang Wei
OBJECTIVE: To conduct a meta-analysis to provide the latest evidence of nonsurgical local salvage options in the first-line radiotherapy failure setting for localized prostate cancer patients. BACKGROUND: Recurrence of localized prostate cancer after primary radiotherapy (RT) remains a clinical challenge. There is no consensus on optimal nonsurgical local salvage therapies, which mainly consist of cryotherapy (CRYO), high-intensity focused ultrasound (HIFU), high/low-dose-rate brachytherapy (HDR/LDR), and stereotactic body radiotherapy (SBRT)...
February 9, 2024: International Journal of Surgery
https://read.qxmd.com/read/38346924/-99m-tcpsma-radioguided-surgery-in-oligorecurrent-prostate-cancer-the-randomised-trace-ii-trial
#24
JOURNAL ARTICLE
Lotte G Zuur, Hilda A de Barros, Matthias N van Oosterom, Anne-Claire Berrens, Maarten L Donswijk, Jeroen J M A Hendrikx, Elise M Bekers, André N Vis, Esther M Wit, Fijs B van Leeuwen, Henk G van der Poel, Pim J van Leeuwen
OBJECTIVE: To investigate whether combination treatment of prostate-specific membrane antigen (PSMA)-based radioguided surgery (RGS) with short-term androgen deprivation therapy (ADT) improves oncological outcomes in men with oligorecurrent prostate cancer (PCa) as compared to treatment with short-term ADT only. METHODS: The TRACE-II study is an investigator-initiated, prospective, randomised controlled clinical trial. Patients (aged >18 years) with hormone-sensitive recurrent PCa after radical prostatectomy or radiotherapy (brachytherapy or external beam radiotherapy), with involvement of ≤2 lymph nodes or local oligorecurrent disease within the pelvis as determined by PSMA positron emission tomography (PET)/computed tomography (CT) are randomly assigned in a 1:1 ratio between 6-month ADT (Arm A) or 6-month ADT plus RGS (Arm B)...
February 12, 2024: BJU International
https://read.qxmd.com/read/38322544/enhancing-androgen-deprivation-therapy-adt-integration-in-prostate-cancer-insights-for-stereotactic-body-radiotherapy-sbrt-and-brachytherapy-modalities
#25
REVIEW
A Gomez-Iturriaga, D Büchser, F Lopez-Campos, X Maldonado
The utilization of Androgen Deprivation Therapy (ADT) in conjunction with Stereotactic Body Radiotherapy (SBRT) and Brachytherapy (BT) boost in prostate cancer treatment is a subject of ongoing debate and evolving clinical practice. While contemporary trends lean towards underutilizing ADT with these modalities, existing evidence suggests that its omission may lead to potentially inferior oncologic outcomes. Recommendations for ADT use should be patient-centric, considering individual risk profiles and comorbidities, with a focus on achieving optimal oncologic outcomes while minimizing potential side effects...
March 2024: Clinical and Translational Radiation Oncology
https://read.qxmd.com/read/38320870/efficacy-and-safety-of-brachytherapy-for-localized-prostate-cancer-in-renal-transplant-recipients
#26
JOURNAL ARTICLE
Kensuke Mitsunari, Hiroki Kurata, Itsuho Ito, Junki Harada, Yuichiro Nakamura, Tomohiro Matsuo, Kojiro Ohba, Yasushi Mochizuki, Ryoichi Imamura
BACKGROUND: Prostate cancer is common among male renal transplant recipients and can present challenges for medical management and patient survival. It is imperative to have a comprehensive understanding of available treatment options in this population to determine the most effective and safe therapies. Brachytherapy, a safe and effective treatment for localized prostate cancer, has not been sufficiently studied in this patient population. Therefore, this study aimed to evaluate the safety and effectiveness of brachytherapy in treating prostate cancer in renal transplant recipients...
February 5, 2024: Transplantation Proceedings
https://read.qxmd.com/read/38312318/alterations-of-sexual-and-erectile-functions-after-brachytherapy-for-prostate-cancer-based-on-patient-reported-questionnaires
#27
JOURNAL ARTICLE
László Gesztesi, Zsuzsa S Kocsis, Kliton Jorgo, Georgina Fröhlich, Csaba Polgár, Péter Ágoston
The aim of the study was to compare the side effects of high-dose-rate brachytherapy (HDRBT) and low-dose-rate brachytherapy (LDRBT), with a particular focus on the effects on sexual functions and sexual well-being (PROMOBRA study, NCT02258087). Localized low-risk and low-intermediate-risk prostate cancer patients were treated with mono LDR ( N  = 123, 145 Gy dose) or mono HDR brachytherapy ( N  = 117, 19/21 Gy). Prior to the treatment and during follow-up (at 3, 6, 9, 12, 18, and 24 months after treatment, and then annually after two years), patients completed patient-reported outcome measurement (PROM) questionnaires EORTC QLQ-PR-25, International Index of Erectile Function (IIEF), and IIEF-5 (SHIM)...
2024: Prostate Cancer
https://read.qxmd.com/read/38308854/development-of-patient-and-catheter-specific-error-thresholds-for-high-dose-rate-prostate-brachytherapy
#28
JOURNAL ARTICLE
Dylan Koprivec, Cedric Belanger, Luc Beaulieu, Philippe Y Chatigny, Anatoly Rosenfeld, Dean Cutajar, Marco Petasecca, Andrew Howie, Joseph Bucci, Joel Poder
BACKGROUND: In-vivo source tracking has been an active topic of research in the field of high-dose rate brachytherapy in recent years to verify accuracy in treatment delivery. Although detection systems for source tracking are being developed, the allowable threshold of treatment error is still unknown and is likely patient-specific due to anatomy and planning variation. PURPOSE: The purpose of this study was to determine patient and catheter-specific shift error thresholds for in-vivo source tracking during high-dose-rate prostate brachytherapy (HDRPBT)...
February 3, 2024: Medical Physics
https://read.qxmd.com/read/38307787/impact-of-the-covid-19-pandemic-on-brachytherapy-and-cancer-patient-outcomes-a-systematic-review
#29
JOURNAL ARTICLE
Shreel Parikh, Yingting Zhang, Zohaib Sherwani, Ritesh Kumar, Nisha Ohri, Imraan Jan, Irina Vergalasova, Salma Jabbour, Lara Hathout
PURPOSE/OBJECTIVE(S): To assess the impact of the COVID-19 pandemic on the use of brachytherapy in patients with gynecologic and prostate cancers including treatment delays, increased burden of mortality, and associated clinical outcomes. MATERIALS/METHODS: A comprehensive search of PubMed, Cochrane Library, CINAHL, Scopus, and Web of Science was conducted using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Databases were searched for studies published through September 2023 using MeSH terms and keywords related to "COVID and brachytherapy...
February 1, 2024: Brachytherapy
https://read.qxmd.com/read/38304110/multiparametric-mri-as-a-predictor-of-psa-response-in-patients-undergoing-stereotactic-body-radiation-therapy-for-prostate-cancer
#30
JOURNAL ARTICLE
Kareem Rayn, Israel Deutsch, Brian Jeffers, Albert Lee, Elizaveta Lavrova, Matthew Gallitto, Mark Mayeda, Mark Hwang, James Yu, Catherine Spina, Lawrence Koutcher
PURPOSE: To maximize the therapeutic ratio, it is important to identify adverse prognostic features in men with prostate cancer, especially among those with intermediate risk disease, which represents a heterogeneous group. These men may benefit from treatment intensification. Prior studies have shown pretreatment mpMRI may predict biochemical failure in patients with intermediate and/or high-risk prostate cancer undergoing conventionally fractionated external beam radiation therapy and/or brachytherapy...
March 2024: Advances in Radiation Oncology
https://read.qxmd.com/read/38302321/prostate-virtual-high-dose-rate-brachytherapy-boost-5-year-results-from-the-prometheus-prospective-multicentre-trial
#31
JOURNAL ARTICLE
Eric Wegener, Mark Sidhom, David Pryor, Joseph Bucci, Kenway Yeoh, Matthew Richardson, Peter Greer, Lee Wilton, Sarah Gallagher, Laurel Schmidt, Sankar Arumugam, Sarah Keats, Simon Brown, Alan Glyde, Jarad M Martin
BACKGROUND AND OBJECTIVE: Despite the high efficacy of high-dose-rate brachytherapy boost (HDRB) in the management of prostate cancer (PC), use of this approach is declining. Similar dosimetry can be achieved using stereotactic body radiotherapy or "virtual HDRB" (vHDRB). The aim of the multicentre, single-arm, phase 2 PROMETHEUS trial (ACTRN12615000223538) was to evaluate the safety and efficacy of vHDRB in patients with PC. METHODS: Patients with intermediate-risk PC or selected patients with high-risk PC were eligible for inclusion...
January 31, 2024: European Urology Oncology
https://read.qxmd.com/read/38296658/keeping-your-best-options-open-with-ai-based-treatment-planning-in-prostate-and-cervix-brachytherapy
#32
REVIEW
Leah R M Dickhoff, Renzo J Scholman, Danique L J Barten, Ellen M Kerkhof, Jelmen J Roorda, Laura A Velema, Lukas J A Stalpers, Bradley R Pieters, Peter A N Bosman, Tanja Alderliesten
PURPOSE: Without a clear definition of an optimal treatment plan, no optimization model can be perfect. Therefore, instead of automatically finding a single "optimal" plan, finding multiple, yet different near-optimal plans, can be an insightful approach to support radiation oncologists in finding the plan they are looking for. METHODS AND MATERIALS: BRIGHT is a flexible AI-based optimization method for brachytherapy treatment planning that has already been shown capable of finding high-quality plans that trade-off target volume coverage and healthy tissue sparing...
January 30, 2024: Brachytherapy
https://read.qxmd.com/read/38281894/establishing-a-fingerprinting-method-for-fast-catheter-identification-in-hdr-brachytherapy-in-vivo-dosimetry
#33
JOURNAL ARTICLE
Daline Tho, Cédric Bélanger, Erik B Jørgensen, Jérémie Tanguay, Haydee M L Rosales, Sam Beddar, Jacob G Johansen, Gustavo Kertzscher, Marie-Claude Lavallée, Luc Beaulieu
PURPOSE: To use quantities measurable during in vivo dosimetry to build unique channel identifiers, that enable detection of brachytherapy errors. MATERIALS AND METHODS: Treatment plan of 360 patients with prostate cancer who underwent high-dose-rate brachytherapy (range, 16-25 catheters; mean, 17) were used. A single point virtual dosimeter was placed at multiple positions within the treatment geometry, and the source-dosimeter distance and dwell time were determined for each dwell position in each catheter...
January 27, 2024: Brachytherapy
https://read.qxmd.com/read/38266199/side-effects-of-permanent-radioactive-iodine-125-implants-brachytherapy-for-prostate-cancer-in-nigeria
#34
JOURNAL ARTICLE
O F Adeyemi, E Bentefour
BACKGROUND: Radioactive seeds implant is a novel option in the developed world for the treatment of organ-confined prostate cancer; however, it is a rare procedure in developing countries, especially in sub-Saharan African countries like Nigeria. The first prostate brachytherapy in Nigeria was performed in 2019 at La'Newton Oncology Clinic using low-dose radioactive iodine-125. The side effects on patients that were treated in three years of its existence in Nigeria are documented in this study...
December 30, 2023: West African Journal of Medicine
https://read.qxmd.com/read/38263844/impact-of-technological-advances-in-treatment-planning-image-guidance-and-treatment-delivery-on-target-margin-design-for-prostate-cancer-radiotherapy-an-updated-review
#35
REVIEW
Jeff D Winter, Varun Reddy, Winnie Li, Tim Craig, Srinivas Raman
Recent innovations in image guidance, treatment delivery, and adaptive radiotherapy (RT) have created a new paradigm for planning target volume (PTV) margin design for patients with prostate cancer. We performed a review of the recent literature on PTV margin selection and design for intact prostate RT, excluding post-operative RT, brachytherapy, and proton therapy. Our review describes the increased focus on prostate and seminal vesicles as heterogenous deforming structures with further emergence of intra-prostatic GTV boost and concurrent pelvic lymph node treatment...
January 23, 2024: British Journal of Radiology
https://read.qxmd.com/read/38261043/functional-outcomes-after-localized-prostate-cancer-treatment
#36
COMPARATIVE STUDY
Bashir Al Hussein Al Awamlh, Christopher J D Wallis, David F Penson, Li-Ching Huang, Zhiguo Zhao, Ralph Conwill, Ruchika Talwar, Alicia K Morgans, Michael Goodman, Ann S Hamilton, Xiao-Cheng Wu, Lisa E Paddock, Antoinette Stroup, Brock B O'Neil, Tatsuki Koyama, Karen E Hoffman, Daniel A Barocas
IMPORTANCE: Adverse outcomes associated with treatments for localized prostate cancer remain unclear. OBJECTIVE: To compare rates of adverse functional outcomes between specific treatments for localized prostate cancer. DESIGN, SETTING, AND PARTICIPANTS: An observational cohort study using data from 5 US Surveillance, Epidemiology, and End Results Program registries. Participants were treated for localized prostate cancer between 2011 and 2012...
January 23, 2024: JAMA
https://read.qxmd.com/read/38247121/evaluation-of-functional-and-oncological-outcomes-of-localized-prostate-cancer-after-different-minimally-invasive-therapeutic-methods-a-single-center-experience
#37
JOURNAL ARTICLE
D V Chinenov, E V Shpot, Y N Chernov, A N Gerasimov, L Y Kazachevskaya, K A Lyapichev, H M Ismailov, Z K Tsukkiev, D O Korolev, L M Rapoport
OBJECTIVES: To study the functional and oncological results of minimally invasive treatment methods: cryoablation, brachytherapy, and high-intensity focused ultrasound (HIFU) therapy of localized prostate cancer in a single hospital. METHODS: One hundred sixty patients with localized prostate cancer were treated with minimally invasive methods (53, 52, 55 patients with cryoablation, brachytherapy and HIFU therapy, respectively). Prostate-specific antigen and evaluation of post-procedure biopsies were used as an assessment...
January 21, 2024: Urologia
https://read.qxmd.com/read/38245406/long-term-outcomes-of-salvage-transurethral-high-dose-rate-brachytherapy-combined-with-external-beam-radiation-therapy-for-anastomotic-recurrence-of-prostate-cancer-after-radical-prostatectomy-a-retrospective-analysis
#38
JOURNAL ARTICLE
Kenta Watanabe, Nobuhiko Kamitani, Naoki Ikeda, Yujiro Kawata, Ryoji Tokiya, Takafumi Hayashi, Yoshiyuki Miyaji, Tsutomu Tamada, Kuniaki Katsui
BACKGROUND: High-dose-rate brachytherapy (HDR-BT) delivers high-dose radiation to local lesions within a short treatment period. There are no reports of salvage transurethral HDR-BT for biochemical recurrence (BCR) after radical prostatectomy. Thus, we aimed to evaluate the usefulness of salvage transurethral HDR-BT with external beam radiation therapy (EBRT) for anastomotic prostate cancer recurrence. METHODS AND MATERIALS: Patients with postoperative prostate cancer who underwent salvage transurethral HDR-BT with EBRT for anastomotic recurrence at our hospital between January 2002 and July 2009 were retrospectively evaluated...
January 19, 2024: Brachytherapy
https://read.qxmd.com/read/38230402/current-status-and-future-readiness-of-indian-radiation-oncologists-to-embrace-prostate-high-dose-rate-brachytherapy-an-indian-brachytherapy-society-survey
#39
JOURNAL ARTICLE
Susovan Banerjee, Soumya Sarkar, Umesh Mahantshetty, Sorun Shishak, Venkatesan Kaliyaperumal, Shyam Singh Bisht, Deepak Gupta, Kushal Narang, Mayur Mayank, V Srinivasan, Vivek Anand, Kanhu Charan Patro, Rajiv Ranjan Prasad, Tejinder Kataria
PURPOSE: This survey aimed to understand the practice pattern and attitude of Indian doctors towards prostate brachytherapy. MATERIAL AND METHODS: A 21-point questionnaire was designed in Google form and sent to radiation oncologists practicing in India, using texts, mails, and social media. Responses were collated, and descriptive statistical analysis was performed. RESULTS: A total of 212 radiation oncologists from 136 centers responded to the survey questionnaire, with majority (66%) being post-specialty training > 6 years...
December 2023: Journal of Contemporary Brachytherapy
https://read.qxmd.com/read/38220257/can-extreme-dose-escalation-with-external-beam-radiation-therapy-and-low-dose-rate-brachytherapy-boost-obviate-the-need-for-long-term-androgen-deprivation-therapy-in-patients-with-high-risk-localized-prostate-cancer
#40
EDITORIAL
Martin T King, Peter F Orio, Anthony V D'Amico
No abstract text is available yet for this article.
February 1, 2024: International Journal of Radiation Oncology, Biology, Physics
keyword
keyword
83387
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.